Taltz (Ixekizumab) is a biologic medicine that suppresses the immune system in order to treat psoriatic arthritis and psoriasis.
Taltz works by blocking interleukin-17 (IL-17). IL-17 is a signalling protein, or cytokine, that regulates the immune system and is related to the body’s inflammatory response. Taltz is itself a type of protein known as a monoclonal antibody.
Taltz is available as a subcutaneous (under the skin) injection. Taltz is available as a pre-filled syringe that is taken every four (4) weeks. The normal dose is 80 mg every four (4) weeks.
Patients starting Taltz will receive two injections (160 mg) initially followed by 80 mg every four (4) weeks after that.
Subcutaneous injections are easy to do compared to other types of injections. Patients can do them quickly at home. A small needle pokes just under the skin to deliver medicine into the “fatty tissue” below.
Important Tests and Risks
Taltz can make it a bit harder for people to fight off infections. Patients taking this medicine should call their doctor they have a fever, think they have an infection, or have been prescribed antibiotics to treat an infection.
Patients should coordinate with their doctor to stop treatment before any surgery. It can be re-started once things have healed and there’s no sign of infection.
Patients should discuss all vaccinations with their doctor because some are not advisable to get while taking Taltz.
It is important to get a TB (tuberculosis) skin test and a chest x-ray before starting Taltz.
It is important for patients who are taking Taltz to get occasional blood tests as requested by their doctor to keep an eye on blood counts and monitor the arthritis.
Drug Identification Number (DIN): 02455102, 02455110